Alzheimers disease
Conditions
Interventions
Sponsors
The First Affiliated Hospital of Xi'an Jiaotong University
Eligibility
Sex/Gender
All
Age
40 Years to 85 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria for the Cognitive Impairment Group: 1. Outpatients and inpatients from the neurology or geriatrics departments of 40 tertiary and secondary hospitals in the northwestern region of China; 2. Aged 40-85 years (including 40 and 85 years), without gender restrictions; 3. A confirmed diagnosis of Alzheimer's disease (AD), vascular cognitive impairment, dementia with Lewy bodies, Parkinson's disease dementia, frontotemporal lobar degeneration, or other subtypes of dementia; 4. Willingness to participate in this study and signing of the informed consent form. Inclusion criteria for the Non-dementia Neurological Diseases Group: 1. Outpatients and inpatients from the neurology and geriatrics departments of 40 tertiary and secondary hospitals in the northwestern region of China; 2. A confirmed diagnosis of one of the following diseases: neurodegenerative diseases (Parkinson's disease, vascular parkinsonism, multiple system atrophy, progressive supranuclear palsy, motor neuron disease), cerebrovascular diseases (acute cerebral infarction, acute spontaneous intracerebral hemorrhage, subarachnoid hemorrhage, non-acute large-area cerebral infarction), neurological immune diseases (multiple sclerosis, neuromyelitis optica spectrum disorders, myasthenia gravis), peripheral nerve diseases (Guillain-Barré syndrome), infectious encephalitis/meningitis, autoimmune encephalitis, active syphilis infection, vitamin B12 deficiency-related neurological diseases; 3. Aged 40-85 years (including 40 and 85 years), without gender restrictions; 4. Willingness to participate in this study and signing of the informed consent form. Inclusion criteria for the Control Group: 1. Without definite neurological diseases; 2. From the same region as the case samples; 3. Aged 40-85 years (including 40 and 85 years), without gender restrictions; 4. Willingness to participate in this study and signing of the informed consent form.
Exclusion criteria
Exclusion criteria: Exclusion criteria for the Case Group: 1. Mixed-type of dementia; 2. Patients with AD who have received lecanemab treatment; 3. Severe dysfunciton of heart, lungs, liver, kidneys, or hematological system, or patients with concurrent tumors; 4. Refused to take blood samples; 5. Refused to sign the informed consent form. Exclusion criteria for the Control Group: 1. Severe dysfunciton of heart, lungs, liver, kidneys, or hematological system, or patients with concurrent tumors; 2. Refused to take blood samples; 3. Refused to sign the informed consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma Aß40;Plasma Aß42;Plasma p-tau181;Plasma p-tau217;Plasma GFAP;Plasma NfL; | — |
Countries
China
Contacts
Public ContactLing Gao
The First Affiliated Hospital of Xi’an Jiaotong University
Outcome results
None listed